Metabolic Diseases  >>  pamrevlumab (FG-3019)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pamrevlumab (FG-3019) / FibroGen
NCT00102297: Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

Completed
1
20
US
FG-3019
FibroGen
Diabetes Mellitus
 
06/07

Download Options